May 22 |
Replimune: Continuing To Justify The Bear Thesis (For Now)
|
May 16 |
Replimune Group GAAP EPS of -$3.24 misses by $0.07
|
May 16 |
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
|
Apr 7 |
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
|
Apr 4 |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 26 |
Replimune Group announces CEO transition
|
Mar 26 |
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
|
Mar 11 |
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
|
Mar 8 |
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
|
Mar 6 |
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
|